Fig. 1 · Structure
Documents & Downloads
Flizasertib
RIP1 Inhibitor
Flizasertib is a selective, reversible inhibitor of receptor-interacting protein kinase 1 (RIP1), demonstrating Kiapp values of 0.00071 μM in human and 0.0013 μM in cynomolgus monkey RIP1. This compound effectively blocks RIP1 autophosphorylation while maintaining RIP1 protein stability. Flizasertib downregulates the production of pro-inflammatory cytokines, including CCL3, CCL4, and IL-1β, making it valuable for research into inflammatory conditions. Additionally, it shows potential in studies related to colitis, ileitis, and cardiac surgery-associated acute kidney injury.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2268739-68-8 |
| Applications | RIP1 Inhibitor |
| Formula | C15H14FN3O |
| Molecular Weight | 271.29 |
| Synonyms | GDC-8264 |
| SMILES | F[C@@H]1C2=NC(C(C3CC3)=O)=NN2[C@H](C4=CC=CC=C4)C1 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.